APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    Hummingbird Bioscience Closes Series B Extension Round after Collecting US$25M

    Hummingbird Bioscience, raised US$25 million from series B extension funding  

    Hummingbird Bioscience Closes Series B Extension Round after Collecting US$25M

    By

    Apac CIOOutlook | Tuesday, May 12, 2020

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    Hummingbird Bioscience, raised US$25 million from series B extension funding 

    Fremont, CA: Hummingbird Bioscience, an innovative biotherapeutics company that aims to discover and conjure the development of breakthrough therapies, has successfully closed an extended Series B investment round after raising US$25 million. The total capital raised by the firm through financing activities and strategic partnerships will account to more than US$65 million to date. 

    The latest Series B extension round was led by the new investor SK Holdings, along with the participation from existing shareholders, including Heritas Capital and SEEDS Capital, the investment wing of Enterprise Singapore.

    The Series B round was extended to US$25 million due to the significant over-subscription, along with the addition of select quality and value-add investors. Hummingbird will use the newly collected funds to accelerate the development of new candidates into clinical trials, strengthen it is scientific and research and development capabilities. 

    “We are delighted to have SK Holdings join our investor base. Hummingbird is building a strong portfolio of promising new therapies that we believe can deliver significant benefits for patients across a broad spectrum of diseases. These new funds give us further resources to develop our early-stage pipeline, and support the clinical development of our lead programs,” said Dr. Piers Ingram, Chief Executive Officer, and co-founder, Hummingbird Bioscience.

    “Heritas Capital is pleased to continue our backing of the Hummingbird team since leading its Series A extended round,” commented Chik Wai Chiew, Executive Director and Chief Executive Officer, Heritas Capital Management. “Even as the COVID-19 pandemic has resulted in a slow-down in investing, we are mindful that backing leading innovative biotech companies, especially players such as Hummingbird, to develop cures for addressing patients’ needs remains our priority.”

    In the first few days of the year, Hummingbird obtained positive data to the lead candidate, HMBD-001, a first-in-class HER3 antibody, and manufacturing of HMBD-002, another first-in-class VISTA antibody. The regulatory submissions to initiate the Phase I research on the two candidates are expected to happen in the second half of 2020.

    More in News

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Enhancing Customer Satisfaction through Omni-Channel Payments

    Enhancing Customer Satisfaction through Omni-Channel Payments

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    Influence of AI on Supply Chain Management

    Influence of AI on Supply Chain Management

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/hummingbird-bioscience-closes-series-b-extension-round-after-collecting-us25m-nwid-7460.html